Pancreatic Cancer Research

ResearcherUniversity of California, San FranciscoActive in the last 2 years

Sam C. Wang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3626-5273; OpenAlex author ID A5040090483. Sources: OpenAlex.

Their work

Papers
8 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
23
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: none · 2015: none · 2016: 1 paper · 2017: 1 paper · 2018: 1 paper · 2019: none · 2020: 1 paper · 2021: none · 2022: none · 2023: 2 papers · 2024: 1 paper

Papers 8

  1. Minimally invasive pancreaticoduodenectomy: A favorable approach for frail patients with pancreatic cancer. Co-author DOI 10.1016/j.surg.2023.12.022↗
  2. Factors associated with failure to operate and its impact on survival in early-stage pancreatic cancer. Co-author DOI 10.1002/jso.27357↗
  3. Hospital Designations and Their Impact on Guideline-Concordant Care and Survival in Pancreatic Cancer. Do They Matter? Co-author DOI 10.1245/s10434-023-13308-7↗
  4. Clinicopathologic Features and Outcomes of Early-Onset Pancreatic Adenocarcinoma in the United States. Co-author DOI 10.1245/s10434-019-08096-y↗
  5. Comparison of Overall Survival Between Preoperative Chemotherapy and Chemoradiotherapy for Resectable Pancreatic Adenocarcinoma. Co-author DOI 10.6004/jnccn.2018.7068↗
  6. Neoadjuvant Therapy Followed by Resection Versus Upfront Resection for Resectable Pancreatic Cancer: A Propensity Score Matched Analysis. Co-author DOI 10.1200/jco.2016.68.5081↗
  7. A Pilot Study Evaluating Serum MMP7 as a Preoperative Prognostic Marker for Pancreatic Ductal Adenocarcinoma Patients. Co-author DOI 10.1007/s11605-015-3057-z↗
  8. Stat3 and MMP7 contribute to pancreatic ductal adenocarcinoma initiation and progression. First author DOI 10.1016/j.ccr.2011.03.002↗

Closest collaborators

The 23 strongest of 23 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Matthew R. Porembka · 7 shared papers, 2016–2024 · strength 0.86
  2. Patricio Marcelo Polanco · 6 shared papers, 2017–2024 · strength 0.81
  3. Adam Charles Yopp · 6 shared papers, 2017–2024 · strength 0.81
  4. Herbert J. Zeh · 4 shared papers, 2020–2024 · strength 0.66
  5. John C. Mansour · 5 shared papers, 2017–2024 · strength 0.63
  6. Gilbert Zvikomborero Murimwa · 2 shared papers, 2023 · strength 0.34
  7. Caitlin A. Hester · 2 shared papers, 2020–2023 · strength 0.28
  8. Amr I. Al Abbas · 1 shared paper, 2024 · strength 0.21
  9. Emile Farah · 1 shared paper, 2024 · strength 0.21
  10. Ali A. Mokdad · 2 shared papers, 2017–2018 · strength 0.15
  11. Javier E. Ordonez · 1 shared paper, 2020 · strength 0.11
  12. Hari Nathan · 1 shared paper, 2016 · strength 0.06
  13. T. Peter Kingham · 1 shared paper, 2016 · strength 0.06
  14. Michael Ian D'Angelica · 1 shared paper, 2016 · strength 0.06
  15. Yuman Fong MD · 1 shared paper, 2016 · strength 0.06
  16. Peter J. Allen · 1 shared paper, 2016 · strength 0.06
  17. William R. Jarnagin · 1 shared paper, 2016 · strength 0.06
  18. John P. Morris · 1 shared paper, 2011 · strength 0.02
  19. Matthew A. Firpo · 1 shared paper, 2011 · strength 0.02
  20. Grace Kim · 1 shared paper, 2011 · strength 0.02
  21. Matthias Hebrok · 1 shared paper, 2011 · strength 0.02
  22. Sean J. Mulvihill · 1 shared paper, 2011 · strength 0.02
  23. Akihisa Fukuda · 1 shared paper, 2011 · strength 0.02

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.